INT53288

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 1995
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 5
Total Number 10
Disease Relevance 4.24
Pain Relevance 8.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (OPN1LW) plasma membrane (OPN1LW) signal transducer activity (OPN1LW)
Anatomy Link Frequency
1A2 1
OPN1LW (Homo sapiens)
Pain Link Frequency Relevance Heat
carbamazepine 1278 100.00 Very High Very High Very High
Gabapentin 96 99.90 Very High Very High Very High
Trigeminal neuralgia 264 99.64 Very High Very High Very High
Pain 606 99.56 Very High Very High Very High
Analgesic 84 99.44 Very High Very High Very High
Pain scale 6 79.32 Quite High
local anesthetic 34 67.20 Quite High
adjuvant analgesic 12 56.48 Quite High
Inflammation 6 56.44 Quite High
antidepressant 18 11.96 Low Low
Disease Link Frequency Relevance Heat
Neuralgia 270 99.64 Very High Very High Very High
Pain 642 99.56 Very High Very High Very High
INFLAMMATION 6 56.44 Quite High
Adhesions 6 55.80 Quite High
Demyelinating Disease 36 5.00 Very Low Very Low Very Low
Hypersensitivity 24 5.00 Very Low Very Low Very Low
Cancer 18 5.00 Very Low Very Low Very Low
Depression 12 5.00 Very Low Very Low Very Low
Ganglion Cysts 12 5.00 Very Low Very Low Very Low
Neuropathic Pain 12 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Clinical impact of the CBZ + ROP association
ROP Binding (association) of associated with carbamazepine
1) Confidence 0.11 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004633 Disease Relevance 0.66 Pain Relevance 1.01
Data reinforce the use of CBZ as a primary tool to control pain in TN patients, as the association CBZ + ROP i) improves the clinical qualities of CBZ, ii) strongly reduces the daily dose of CBZ, and iii) reduces the potential side effects attributed to high doses of CBZ.



ROP Binding (association) of associated with pain, trigeminal neuralgia and carbamazepine
2) Confidence 0.09 Published 2010 Journal Journal of pain research Section Abstract Doc Link PMC3004633 Disease Relevance 0.63 Pain Relevance 1.43
The number needed to treat for the association CBZ + ROP over the CBZ protocol reduced from 5 at the end of the 4-week treatment to 3 after the 5-month follow-up.
ROP Binding (association) of associated with carbamazepine
3) Confidence 0.09 Published 2010 Journal Journal of pain research Section Abstract Doc Link PMC3004633 Disease Relevance 0.76 Pain Relevance 1.62
This suggests that, as was previously demonstrated for the gabapentin and ROP association,21 a potentiation or synergism between the AE and local analgesic effect occurs when CBZ and ROP are associated in the same protocol.
ROP Binding (associated) of associated with analgesic, gabapentin and carbamazepine
4) Confidence 0.09 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004633 Disease Relevance 0.55 Pain Relevance 1.37
Both protocols resulted in a decrease of pain intensity and number of pain crises, but only the association CBZ + ROP showed i) a significant stronger reduction in pain intensity at month 6 and ii) a significant decrease in the daily dose of CBZ given to patients (both at day 29 and month 6).
ROP Binding (association) of associated with pain and carbamazepine
5) Confidence 0.09 Published 2010 Journal Journal of pain research Section Abstract Doc Link PMC3004633 Disease Relevance 1.03 Pain Relevance 2.05
This suggests that, as was previously demonstrated for the gabapentin and ROP association,21 a potentiation or synergism between the AE and local analgesic effect occurs when CBZ and ROP are associated in the same protocol.
ROP Binding (association) of associated with analgesic, gabapentin and carbamazepine
6) Confidence 0.08 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004633 Disease Relevance 0.61 Pain Relevance 1.42
CONCLUSIONS: Ropivacaine was metabolized to PPX, 3'-OH Rop, and 4'-OH Rop by hepatic P450.
Rop Binding (metabolized) of
7) Confidence 0.03 Published 1995 Journal Anesthesiology Section Body Doc Link 7832304 Disease Relevance 0 Pain Relevance 0
CONCLUSIONS: Ropivacaine was metabolized to PPX, 3'-OH Rop, and 4'-OH Rop by hepatic P450.
Rop Binding (metabolized) of
8) Confidence 0.03 Published 1995 Journal Anesthesiology Section Body Doc Link 7832304 Disease Relevance 0 Pain Relevance 0
Anti CYP3A2 and 1A2 antibodies inhibited the formation of PPX and 3'-OH Rop in human hepatic microsomes, respectively.
Rop Neg (inhibited) Binding (formation) of in 1A2
9) Confidence 0.03 Published 1995 Journal Anesthesiology Section Body Doc Link 7832304 Disease Relevance 0 Pain Relevance 0
Formation of PPX in rat hepatic microsomes was inhibited by anti CYP3A2, but not by CYP2C11 antibody, and formation of 3'-OH Rop was inhibited by CYP1A2 and 2D1 antibodies.
Rop Neg (not) Binding (formation) of
10) Confidence 0.03 Published 1995 Journal Anesthesiology Section Body Doc Link 7832304 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox